Related Experiment Video
Updated: Mar 4, 2026
08:57
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
2.7K
BCOR-CCNB3 Undifferentiated Sarcoma-Does Immunohistochemistry Help in the Identification?
Kathrin Ludwig1, Rita Alaggio2, Angelica Zin3
11 Pathological Anatomy-Cardiovascular Pathology, Department of Cardiac, Thoracic and Vascular Sciences, University Hospital Padua, Padua, Italy.
Summary
New research identifies BCOR-CCNB3 fusion sarcomas, previously unclassified. These rare tumors, exclusively in males, show distinct morphological and immunohistochemical features, aiding diagnosis.
Area of Science:
- Oncology
- Pathology
- Genetics
Background:
- Undifferentiated/unclassified sarcomas represent a heterogeneous group of tumors.
- Recent advancements allow identification of specific genetic subgroups within this category.
- BCOR-CCNB3 fusion sarcoma is a newly recognized entity with overlapping features with Ewing sarcoma and other soft tissue sarcomas, posing diagnostic challenges.
Purpose of the Study:
- To investigate the morphological and immunohistochemical characteristics of BCOR-CCNB3 positive sarcomas.
- To identify potential diagnostic markers for this specific sarcoma subtype.
Main Methods:
- Retrospective review of two sarcoma series (632 and 121 cases).
- Identification of BCOR-CCNB3 fusion-positive tumors using CCNB3 immunohistochemistry and/or RT-PCR.
- Detailed morphological re-evaluation and immunohistochemical analysis for CCNB3, SATB2, and Pax8.
Main Results:
- Eleven out of 753 tumors harbored the BCOR-CCNB3 fusion.
- These sarcomas occurred exclusively in males (mean age 12.9 years) and were predominantly axially located.
- Pathognomonic features included spindled or round cells, vesicular nuclei, finely dispersed chromatin, inconspicuous nucleoli, and an arciform vascular pattern.
- Over 50% of cases showed positive staining for SATB2 and Pax8.
- CCNB3 was confirmed as a valuable ancillary marker.
Conclusions:
- BCOR-CCNB3 fusion sarcoma is a distinct entity within undifferentiated/unclassified sarcomas.
- Specific morphological features and immunohistochemical markers (CCNB3, SATB2, Pax8) can aid in its diagnosis.
- Further investigation into SATB2 and Pax8 utility for identifying these rare sarcomas is warranted.
